Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
FDA Approval Insights: Ponatinib in Ph+ ALL
Insider Insights: Unveiling Takeaways from AACR 2024
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma
Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma